Hectorol Related Published Studies
Well-designed clinical trials related to Hectorol (Doxercalciferol)
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. [2008.04.15]
Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. [2004.05]
Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. [2000.09]
Well-designed clinical trials possibly related to Hectorol (Doxercalciferol)
Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice. [2003.04]
Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. [1998]
Other research related to Hectorol (Doxercalciferol)
Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. [2008.01]
Doxercalciferol treatment of secondary hyperparathyroidism. [2006.11]
Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients. [2006.05]
Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. [2005.11]
Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy. [2003.06]
Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone. [2003.04]
Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient. [2002.08]
Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. [2001.03]
Other possibly related research studies
Growth inhibition of cancer cells by an active metabolite of a novel vitamin D prodrug. [2005.11]
Are new vitamin D analogues in renal bone disease superior to calcitriol? [2005.03]
Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. [2004.09]
Calcimimetics versus vitamin D: what are their relative roles? [2004]
Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. [2003.09.15]
[Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient] [2003.05]
Prevention and treatment of secondary hyperparathyroidism: still a challenge for the nephrologist? [2003.07]
A review of intravenous versus oral vitamin D hormone therapy in hemodialysis patients. [2003.05]
Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice. [2002]
Vitamin D analogues for secondary hyperparathyroidism. [2002]
Comparative review of the pharmacokinetics of vitamin D analogues. [2002.09]
Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. [2002.09]
Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. [2002.05]
Vitamin D analogs for the treatment of secondary hyperparathyroidism. [2002]
Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. [2001.11]
Therapeutic uses of vitamin D analogues. [2001.11]
1alpha-hydroxyvitamin D2 is less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized rats. [2001.04]
1 alpha-Hydroxy-vitamin D2: a new look at an 'old' compound. [1996]
Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women. [1994.05]
Rickets of prematurity: a case report. [1991.12]
Effects of vitamin D2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3-E1 osteoblastic cells. [1991]
Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. [2005.08]
Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism. [2002]
Clinical trials in cancer prevention: current results and perspectives for the future. [2004.12]
Management of secondary hyperparathyroidism of dialysis patients. [2003.10]
Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4. [2003.06]
Bone disease in uremic patients: advances in PTH suppression. [2002.11]
Use of vitamin D analogs in chronic renal failure. [2002.07]
Strategies to minimize bone disease in renal failure. [2001.12]
What is the optimal regimen for vitamin D? [1999.12]
Mortality risk among hemodialysis patients receiving different vitamin D analogs. [2006.11]
Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? [2007.03]
[New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure] [2007.05]
Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. [2006.03]
[Treatment of hypoparathyroidism by active vitamin D] [2007.08]
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. [2007.06]
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. [2008.01]
Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. [2007]
Vitamin D receptor activator selectivity in the treatment of secondary hyperparathyroidism: understanding the differences among therapies. [2007]
1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. [2007.12]
Improved patient outcomes in chronic kidney disease: optimizing vitamin D therapy. [2008.03]
Prescriptions for vitamin D among patients taking antiresorptive agents in Canada. [2007.06]
Pharmacokinetics of vitamin D toxicity. [2008.08]
|
